NDA 208723 · Actavis LLC
Levoleucovorin Calcium
Levoleucovorin Calcium · Intravenous
OrphanDiscontinuedLast checked: Nov 20, 2026Latest source record: Mar 23, 2017 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2016
Sep 29, 2016
Approved uses
1
Original approval plus efficacy supplements
Registered trials
1,253
339 Phase 3, 166 recruiting
FAERS reports
3,810
3,758 serious, 549 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 29, 2016 Original approval · Type 5 - New Formulation or New Manufacturer OrphanLetterLabelReview
1 products under this application
- LEVOLEUCOVORIN CALCIUM · LEVOLEUCOVORIN CALCIUM EQ 175MG BASE/VIAL · POWDER, INTRAVENOUS · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Levoleucovorin" as an intervention, any sponsor and status, largest first.
- Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic LymphomaPivotal-lookingCompleted
Children's Oncology GroupResearch network
NCT01190930 · 9,350 participants · Start Aug 11, 2010 · Primary completion Mar 31, 2019
Drug: Cyclophosphamide; Cytarabine and 8 more · For: Acute Lymphoblastic Leukemia; Adult B Lymphoblastic Lymphoma; Ann Arbor Stage I B Lymphoblastic Lymphoma and 7 more
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 243 sites in all
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic LeukemiaPivotal-lookingActive, not recruiting
National Cancer Institute (NCI)NIH
NCT03914625 · 6,720 participants (planned) · Start Jul 3, 2019 · Primary completion Sep 30, 2027
Drug: Asparaginase Erwinia chrysanthemi; Blinatumomab and 13 more · For: B Acute Lymphoblastic Leukemia; B Lymphoblastic Lymphoma; Down Syndrome
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 228 sites in all
- Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLyPivotal-lookingRecruiting
Children's Oncology GroupResearch network
NCT03959085 · 5,951 participants (planned) · Start Oct 31, 2019 · Primary completion Mar 31, 2032
Drug: Blinatumomab; Calaspargase Pegol and 14 more · For: B Acute Lymphoblastic Leukemia; B Lymphoblastic Lymphoma; Central Nervous System Leukemia and 2 more
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 231 sites in all
- Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive MutationsPivotal-lookingCompleted
National Cancer Institute (NCI)NIH
NCT02883049 · 5,949 participants · Start Feb 29, 2012 · Primary completion Dec 31, 2022
Drug: Clofarabine; Cyclophosphamide and 14 more · For: B Acute Lymphoblastic Leukemia; B Acute Lymphoblastic Leukemia, BCR-ABL1-Like; Central Nervous System Leukemia and 1 more
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 239 sites in all
- Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic LeukemiaPivotal-lookingCompleted
Children's Oncology GroupResearch network
NCT00103285 · 5,377 participants · Start Apr 11, 2005 · Primary completion Dec 30, 2013
Drug: Cyclophosphamide; Cytarabine and 8 more · For: Acute Lymphoblastic Leukemia; Childhood B Acute Lymphoblastic Leukemia
Sites: Birmingham, Alabama; Mobile, Alabama; Mesa, Arizona · 236 sites in all
- Risk-Adjusted Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic LeukemiaPivotal-lookingStatus unknown
University Hospital, MotolAcademic, hospital or other
NCT00764907 · 4,000 participants (planned) · Start Nov 2002 · Primary completion Oct 2007
Drug: asparaginase; cyclophosphamide and 13 more · For: Leukemia
Sites: Prague, Czechia
- FOLFOX-4 3months Versus 6 Months and Bevacizumab as Adjuvant Therapy for Patients With Stage II/III Colon CancerPivotal-lookingCompleted
Gruppo Italiano per lo studio dei Carcinomi dell'Apparato DigerenteAcademic, hospital or other
NCT00646607 · 3,756 participants · Start Jun 2007 · Primary completion Apr 2013
Drug: FOLFOX (Oxaliplatin, 5Fluorouracil, Lederfolin); FOLFOX (Oxaliplatin, 5Fluorouracil, Lederfolin) · For: Colon Cancer
Sites: Casale Monferrato, Italy; Ancona, Italy; Fabriano, Italy · 111 sites in all
- Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for High Risk Stage II or Stage III Colon CancerPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT00112918 · 3,451 participants · Start Dec 2004 · Primary completion Jun 2010
Drug: Bevacizumab; Capecitabine and 3 more · For: Colorectal Cancer
Sites: Los Angeles, California
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- nausea303
- off label use280
- neutropenia259
- diarrhoea254
- decreased appetite191
- vomiting179
- malignant neoplasm progression169
- neuropathy peripheral159
- pyrexia144
- asthenia141
- neutrophil count decreased141
- myelosuppression136
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2005 | 1 |
| 2007 | 1 |
| 2008 | 6 |
| 2009 | 16 |
| 2010 | 2 |
| 2011 | 112 |
| 2012 | 195 |
| 2013 | 9 |
| 2014 | 19 |
| 2015 | 21 |
| 2016 | 10 |
| 2017 | 15 |
| 2018 | 113 |
| 2019 | 89 |
| 2020 | 77 |
| 2021 | 266 |
| 2022 | 482 |
| 2023 | 804 |
| 2024 | 593 |
| 2025 | 614 |
| 2026 | 365 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Levoleucovorin Calcium (Levoleucovorin Calcium)
2024 spending
$9K
Beneficiaries
n/a
29 claims
Per beneficiary
n/a
$3.64 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $77,847 |
| 2021 | $69,840 |
| 2022 | $12,035 |
| 2023 | $13,137 |
| 2024 | $8,605 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Phase I trial of apatinib and paclitaxel+oxaliplatin+5-FU/levoleucovorin for treatment-naïve advanced gastric cancer.
Zhao S, Su L, Huang F, et al. · Cancer Sci 2024 · Clinical Trial, Phase I
- Bioequivalence of oral and injectable levoleucovorin and leucovorin.
DeVito JM, Kozloski GD, Tonelli AP, et al. · Clin Pharm 1993 · Clinical Trial, Randomized Controlled Trial
- First-line sunitinib plus FOLFIRI in Japanese patients with unresectable/metastatic colorectal cancer: a phase II study.
Tsuji Y, Satoh T, Tsuji A, et al. · Cancer Sci 2012 · Clinical Trial, Phase II, Research Support, Non-U.S. Gov't
- Doxifluridine and leucovorin: an oral treatment combination in advanced colorectal cancer.
Bajetta E, Colleoni M, Di Bartolomeo M, et al. · J Clin Oncol 1995 · Clinical Trial, Comparative Study
- High-versus low-dose levo-leucovorin as a modulator of 5-fluorouracil in advanced colorectal cancer: a 'GISCAD' phase III study. Italian Group for the Study of Digestive Tract Cancer.
Labianca R, Cascinu S, Frontini L, et al. · Ann Oncol 1997 · Clinical Trial, Clinical Trial, Phase III
- Phase 1 study of efatutazone, a novel oral peroxisome proliferator-activated receptor gamma agonist, in combination with FOLFIRI as second-line therapy in patients with metastatic colorectal cancer.
Komatsu Y, Yoshino T, Yamazaki K, et al. · Invest New Drugs 2014 · Clinical Trial, Phase I, Research Support, Non-U.S. Gov't
Sponsor: Actavis LLC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.